Skip to content

Bonus Episode: Psychedelic Research Inside an Academic Medical Center with Scott Thompson, PhD

October 27, 2026 · 1 h 12 min

Show notes

In this bonus episode, Dr. Ben Everett speaks with Scott Thompson, PhD, professor of psychiatry at the University of Colorado School of Medicine, where he directs the Novel Therapeutics in the Brain and Behavior Innovation Center and leads the Psychedelic Public Policy Partnership. Drawing on more than 40 years of synaptic research, Dr. Thompson describes how an unexpected finding on SSRI action led his lab to show in mice that psilocybin's antidepressant-like effects persisted even when the 5-HT2A receptor was blocked, and what that finding means for the question of whether the psychedelic experience itself is the medicine.

As psychedelic compounds advance through late-stage development, clinicians face open questions about mechanism, trial design, safety, and access. This conversation covers functional unblinding and the search for objective endpoints such as anhedonia, what it takes to run Schedule I research inside an academic medical center, and real-world outcome and safety data from more than 2,300 people who received regulated psilocybin services in Colorado and Oregon. Dr. Thompson also discusses the role of psychotherapy, the evidence on microdosing, and phase III programs including Definium's DT120 LSD formulation and Beckley Atai's intranasal 5-MeO-DMT.

KEY EPISODE HIGHLIGHTS: A SUPERCHARGED SSRI [45:30]

“psychedelics do what SSRIs do. They just do it more potently and more quickly.”

Dr. Thompson's working hypothesis frames psychedelics as faster, stronger versions of a mechanism clinicians already use every day, which shapes how his lab tests whether the trip is required.

A DOSE CEILING IN REAL-WORLD DATA [27:31]

“people who got doses of psilocybin less than thirty milligrams displayed the same improvement in symptoms as people who got doses more than thirty-five”

Outcome data from more than 2,300 regulated psilocybin clients suggest a threshold rather than a linear dose-response, challenging the assumption that higher doses yield greater benefit.

MICRODOSING AND EXPECTANCY [31:00]

“There's strong evidence now that microdosing is primarily a placebo effect.”

Placebo-controlled studies show benefit tracks what participants believed they received rather than what they actually took, useful context when patients ask about microdosing.

CHAPTERS:

00:00 – Introduction: Is the Experience the Medicine?

02:00 – From Basel and Zurich to Psilocybin and Synaptic Plasticity

07:30 – Psychedelic Research and Policy at CU Anschutz

10:30 – Functional Unblinding and the Search for Objective Endpoints

15:00 – Facilitator Support, Placebo Response, and Predictive Biomarkers

20:00 – Building Safety Into Colorado's Regulated Psilocybin Services

24:30 – Real-World Outcomes From Colorado and Oregon Psilocybin Clients

28:00 – Dose Thresholds, MEQ-30 Scores, and the Evidence on Microdosing

32:00 – Running Schedule I Research: Regulation, Funding, and INDs

36:30 – Safety Signals: Psychosis, Suicidality, and Adverse Event Follow-Up

43:00 – Blocking the 5-HT2A Receptor: Is the Trip Necessary?

47:30 – Cost, Access, and Shorter-Acting Psychedelics

50:30 – Receptor Promiscuity and Non-Hallucinogenic Compounds

53:30 – The Role of Psychotherapy in Psychedelic Treatment

59:30 – Definium's DT120: Phase III Data, Payer Realities, and Dose Selection

01:07:00 – Beckley Atai's 5-MeO-DMT and Other Short-Acting Compounds

01:09:30 – Clinical Takeaways

LINKS:

Full transcript and show notes:

https://www.psychiatrist.com/jcp/ep27-psychedelic-research-academic-medical-center-scott-thompson/

Journal of Clinical Psychiatry

https://www.psychiatrist.com/jcp/

Publisher of peer-reviewed research discussed in this episode.

Dr. Scott Thompson – LinkedIn

https://www.linkedin.com/in/scott-thompson-241a1a15/

Harnessing Psilocybin (Hesselgrave et al., PNAS, 2021)

https://doi.org/10.1073/pnas.2022489118

Dr. Thompson's mouse study showing psilocybin's antidepressant-like effects persisted despite 5-HT2A receptor blockade.

Colorado Natural Medicine Program

https://dpo.colorado.gov/NaturalMedicine

State program for regulated psilocybin services discussed in this episode.

Definium Therapeutics

https://definiumtx.com

Developer of DT120, the LSD formulation with phase III results in MDD and GAD.

#Psilocybin #PsychedelicMedicine #LSD #Neuroplasticity #FunctionalUnblinding

All episodes of The Journal of Clinical Psychiatry Podcast

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.